Edition:
India

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

10.99USD
24 May 2019
Change (% chg)

$-0.05 (-0.45%)
Prev Close
$11.04
Open
$11.11
Day's High
$11.11
Day's Low
$10.80
Volume
31,304
Avg. Vol
69,534
52-wk High
$20.56
52-wk Low
$9.23

Latest Key Developments (Source: Significant Developments)

Concert Pharmaceuticals Says Intend To Appeal Decision From Patent Trial
Tuesday, 9 Apr 2019 

April 8 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES DECISION FROM PATENT TRIAL AND APPEAL BOARD IN IPR PROCEEDING.CONCERT PHARMACEUTICALS INC - DISAPPOINTED IN OUTCOME FROM PATENT TRIAL AND APPEAL BOARD IN IPR PROCEEDING.CONCERT PHARMACEUTICALS INC - INTEND TO APPEAL DECISION AS WE WORK TO CREATE ADDITIONAL INTELLECTUAL PROPERTY PROTECTING CTP-543.CONCERT PHARMACEUTICALS INC - DEVELOPMENT TIMELINES FOR CTP-543 REMAIN ON TRACK..CONCERT PHARMACEUTICALS INC - DECISION IS SPECIFIC TO CERTAIN PATENT CLAIMS COVERING CTP-543 AND DOES NOT AFFECT OTHER PROGRAMS IN PORTFOLIO.  Full Article

Concert Pharmaceuticals Reports Year Ended 2018 Financial Results
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS.CONCERT PHARMACEUTICALS INC - CTP-692 POISED TO ADVANCE INTO PHASE 2 DEVELOPMENT BY YEAR END 2019 AS ADJUNCTIVE TREATMENT FOR SCHIZOPHRENIA.CONCERT PHARMACEUTICALS INC - REVENUE WAS $10.5 MILLION FOR YEAR ENDED DECEMBER 31, 2018, COMPARED TO $143.9 MILLION FOR YEAR ENDED DECEMBER 31, 2017.  Full Article

Concert Pharmaceuticals Reports Positive Results For CTP-543
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM INTERIM ANALYSIS OF PHASE 2A TRIAL IN PATIENTS WITH ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG TWICE-DAILY COHORT.CONCERT PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED.CONCERT PHARMACEUTICALS - RESULTS FROM COMPLETE CTP-543 PHASE 2A TRIAL, INCLUDING 12 MG COHORT, EXPECTED IN Q3 2019.  Full Article

Concert Pharmaceuticals Amends Protocol Of Phase 2A Trial To Evaluate 12 Mg Twice-Daily Dose Cohort Of Ctp-543 For Treatment Of Alopecia Areata
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS AMENDS PROTOCOL OF PHASE 2A TRIAL TO EVALUATE 12 MG TWICE-DAILY DOSE COHORT OF CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - COMPANY ON TRACK TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG TWICE-DAILY COHORTS IN Q4 OF 2018.CONCERT PHARMACEUTICALS INC - PROTOCOL AMENDMENT PROVIDES FOR ADDITIONAL PATIENTS TO BE ENROLLED IN TRIAL.  Full Article

Concert Pharma Says FDA Granted Fast Track Designation To CTP-543
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Concert Pharmaceuticals Inc ::FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA.CONCERT PHARMA SAYS U.S. FDA GRANTED FAST TRACK DESIGNATION FOR CO'S CTP-543.  Full Article

Concert Pharmaceuticals Announces Appointment Of Marc Becker As CFO
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER.CONCERT PHARMACEUTICALS INC - ANNOUNCED APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 4, 2018.  Full Article

Concert Pharmaceuticals reports Q3 earnings per share $5.61
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update.Q3 earnings per share $5.61.Q3 revenue $143.8 million.Q3 revenue view $11,700 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Concert Pharmaceuticals Inc - ‍Expects cash, cash equivalents and investments as of September 30, 2017 to be sufficient to fund company into 2021​.  Full Article

Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial.Concert Pharmaceuticals Inc - ‍phase 2a trial on track to complete in second half of 2018​.  Full Article

Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​.  Full Article